Akari Therapeutics (AKTX) Stock: Gaining Big On Fast Track Designation


Akari Therapeutics PLC (ADR) (NASDAQ: AKTX)

Akari Therapeutics is having an overwhelmingly strong start to the day this morning, and for good reason. The company announced that it has received Fast Track Designation with regard to a key clinical candidate. As a result, investors are excited and the stock is spiking. As can be expected, our partners at Trade Ideas were the first to inform us of the gains. Currently (8:11), AKTX is trading at $8.35 per share after a gain of $1.37 per share or 19.56% thus far today.

AKTX Receives Fast Track Designation

As mentioned above, Akari Therapeutics is having an overwhelmingly strong start in the pre-market hours after announcing that it has received Fast Track Designation from the US Food and Drug Administration. The designation is for Coversin(TM) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in patients who have polymorphism conferring eculizumab resistance. In a statement, Dr. Gur Roshwalb, CEO at AKTX, had the following to offer…

We are very proud of the continued advancement of our Coversin program for the treatment of PNH in patients with or without polymorphism… The FDA fast track designation recognizes the unmet need in patients with PNH who cannot be treated with the current standard of care due to polymorphisms.”

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on AKTX. In particular, we’ll be watching the continued work surrounding Coversin and we are excited to do so given all of the positive news surrounding this potentially life-changing treatment. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks.

What Do You Think?

Where do you think AKTX is headed moving forward? Join the discussion in the comments below or on StockTwits!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required

[Image Courtesy of Max Pixel]


Please enter your comment!
Please enter your name here